NRX Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. Co. is developing therapeutics based on its N-methyl-D-aspartate (NMDA) platform for the treatment of central nervous system disorders, specifically suicidal bipolar depression, chronic pain, and post-traumatic stress disorder (PTSD). Co. has two lead compounds, NRX-100, a proprietary presentation of ketamine and NRX-101, a fixed-dose combination of D-cycloserine (DCS) and lurasidone. Co. is developing NRX-101, a Food and Drug Administration (FDA)-designated investigational therapy for suicidal treatment-resistant bipolar depression and chronic pain. We show 22 historical shares outstanding datapoints in our coverage of NRXP's shares outstanding history.
Understanding the changing numbers of NRXP shares outstanding — and
comprehending the concept of differing number of shares outstanding in general comparing companies like NRXP versus peers —
is critical for investors. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies.
Furthermore, via issuance of new shares over time, or the repurchase of existing shares, the number of shares outstanding can fluctuate over the course of history.
With this page we aim to empower investors researching NRXP by allowing them to research NRXP shares outstanding history
as well as any other stock in our coverage universe. |
Free NRXP Email Alerts:
Video: Shares Outstanding Importance
